CJC-1295 (without DAC) and Turinabol Interaction

Monitor
Mechanism-based 51% confidence

CJC-1295 (without DAC) and Turinabol have an interaction requiring monitoring for interaction with 51% confidence. Both CJC-1295 (without DAC) and Turinabol can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. These compounds primarily affect different organ systems.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Turinabol

Oral Anabolic Steroid | Lean Gains & Athletic Performance

Turinabol exerts its anabolic effects through binding to the intracellular androgen receptor (AR), promoting nitrogen retention, protein synthesis, and positive nitrogen balance in skeletal muscle. The 4-chloro substitution on the A-ring is the defining structural feature, serving two key pharmacological purposes: it completely prevents aromatization by the aromatase enzyme (blocking conversion to estrogenic metabolites), and it reduces the compound's androgenic potency relative to its anabolic activity.

Half-life: ~16 hours Typical dose: 30-60 mg/day (male) anabolic
androgen receptoraromatase androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 (without DAC), Turinabol). Monitor accordingly.
2x 2 estrogenic compounds (CJC-1295 (without DAC), Turinabol). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), Turinabol). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with Turinabol?

Yes, but with caution. Both CJC-1295 (without DAC) and Turinabol can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. Regular monitoring is advised.

Is CJC-1295 (without DAC) and Turinabol safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, estrogenic, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and Turinabol?

Both CJC-1295 (without DAC) and Turinabol can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and Turinabol?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Turinabol has a half-life of ~16 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs Turinabol

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.